Table 1.
Comparison of baseline clinical characteristics between the MACE1 group (all-cause mortality and rehospitalization for severe heart failure) and the NMACE1 group.
| Factors | MACE (n=63) | NMACE (n=1495) | χ2/t | P |
|---|---|---|---|---|
| Demographics and clinical data, n (%) | ||||
| Male sex | 46 (73.0) | 1120 (74.9) | 0.116 | 0.733 |
| Age ≥65 years | 32 (50.8) | 340 (22.7) | 26.171 | <0.001 |
| Hyperlipidemia | 36 (57.1) | 846 (56.6) | 0.008 | 0.931 |
| Hypertension | 35 (55.6) | 880 (58.9) | 0.273 | 0.601 |
| T2DM | 14 (22.2) | 380 (25.4) | 0.327 | 0.568 |
| History of stroke | 16 (25.4) | 206 (13.8) | 6.678 | 0.010 |
| History of TIA | 0 (0.0) | 5 (0.3) | 0.211 | 0.646 |
| History of HF | 20 (31.7) | 138 (9.2) | 33.629 | <0.001 |
| History of CGS | 8 (12.7) | 17 (1.1) | 51.178 | <0.001 |
| Current smoking | 29 (46.0) | 780 (52.2) | 0.914 | 0.339 |
| Family history of CAD | 5 (7.9) | 214 (14.3) | 2.036 | 0.154 |
| UA | 15 (23.8) | 601 (40.2) | 6.794 | 0.009 |
| STEMI | 34 (54.0) | 660 (44.1) | 2.360 | 0.124 |
| NSTEMI | 14 (22.2) | 234 (15.7) | 1.950 | 0.163 |
| Laboratory data, n (%) | ||||
| WBC↑ | 25 (40.3) | 485 (32.5) | 1.640 | 0.200 |
| PLT↑ | 4 (6.3) | 113 (7.6) | 0.127 | 0.721 |
| | NEU |↑ | 28 (45.9) | 519 (34.8) | 3.188 | 0.074 |
| | LYM |↓ | 16 (26.2) | 259 (17.3) | 3.174 | 0.075 |
| | MON |↑ | 16 (26.2) | 314 (21.0) | 0.947 | 0.331 |
| MPV↑ | 1 (1.7) | 5 (0.3) | 2.656 | 0.103 |
| PDW↑ | 1 (1.7) | 15 (1.0) | 0.264 | 0.607 |
| NLR↑ | 46 (75.4) | 780 (52.2) | 12.631 | <0.001 |
| MLR↑ | 31 (50.8) | 498 (94.1) | 7.961 | 0.005 |
| PLR↑ | 19 (31.1) | 192 (12.9) | 16.703 | <0.001 |
| ALB↓ | 7 (11.7) | 69 (4.6) | 6.077 | 0.014 |
| CK-MB↑ | 36 (65.5) | 688 (50.5) | 4.746 | 0.029 |
| Cr↑ | 6 (10.0) | 36 (2.4) | 12.638 | <0.001 |
| Echocardiography, n (%) | ||||
| LA↑ | 20 (35.1) | 338 (25.1) | 2.876 | 0.090 |
| LVEDD↑ | 18 (31.6) | 334 (24.7) | 1.363 | 0.243 |
| EF <40% | 8 (14.0) | 33 (2.4) | 25.971 | <0.001 |
| Coronary angiogram, n (%) | ||||
| One vascular lesion | 16 (25.4) | 472 (31.6) | 1.072 | 0.301 |
| Two vascular lesions | 22 (34.9) | 475 (31.8) | 0.276 | 0.599 |
| Three vascular lesions | 25 (39.7) | 548 (36.7) | 0.238 | 0.625 |
| Drugs, n (%) | ||||
| Aspirin | 49 (77.8) | 1483 (99.2) | 169.020 | <0.001 |
| Clopidogrel | 43 (68.3) | 1182 (79.1) | 4.203 | 0.040 |
| Ticagrelor | 5 (7.9) | 300 (20.1) | 5.650 | 0.017 |
| β-blockers | 32 (50.8) | 766 (51.2) | 0.005 | 0.945 |
| ACEIs/ARBs | 19 (30.2) | 679 (45.4) | 5.692 | 0.017 |
| Statins | 49 (77.8) | 1478 (98.9) | 137.816 | <0.001 |
| CCB | 7 (11.1) | 258 (17.3) | 1.618 | 0.203 |
| Diuretics | 11 (17.5) | 99 (6.6) | 10.822 | 0.001 |
MACE, major adverse cardiac events; NMACE, non-major adverse cardiac events; TIA, transient ischemic attack; T2DM, type 2 diabetes mellitus; HF, heart failure; CGS, cardiogenic shock; CAD, coronary artery disease; UA, unstable angina; STEMI: ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; WBC, white blood cells; PLT, platelets; | NEU |, absolute value of neutrophils; | LYM |, absolute value of lymphocytes; | MON |, absolute value of monocytes; MPV, mean platelet volume; PDW, platelet distribution width; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ALB, albumin; CK-MB, creatine phosphokinase isoenzyme; Cr, creatinine; LA, left atrium; LVEDD, left ventricular end-diastolic diameter; EF, ejection fraction; ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; CCB, amlodipine besylate tablet; ↑, above the upper limit of normal values; ↓, below the lower limit of normal values.